Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage v Japanese patients on maintenance renal replacement therapy

Clinical and Experimental Nephrology

Volumn 18, Issue 1, 2014, Pages 135-143

  Fukagawa, Masafumi ^a   Kasuga, Hirotake ^b   Joseph, Devanand ^c   Sawata, Hiroshi ^c   Junge, Guido ^c   Moore, Alan ^c   Akiba, Takashi ^d  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kaikoukai Central Clinic   (Japan)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

End stage renal disease (ESRD); Haemodialysis (HD); Oral phosphate binders (OPB); Renal replacement therapy (RRT); SBR759; Serum phosphate

Indexed keywords

CALCIUM PHOSPHATE; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SBR 759; TRANSFERRIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CHELATING AGENT; DRUG COMBINATION; FERRIC ION; STARCH;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANUS FISSURE; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FECES COLOR; FEMALE; GINGIVA BLEEDING; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; VOMITING; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; ETHNOLOGY; JAPAN; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

BIOMARKERS; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; JAPAN; LINEAR MODELS; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; STARCH; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896727069     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0815-7     Document Type: Article

References (16)

1. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014-21.
2. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-83.
3. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-87.
4. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol. 2006;38:739-43.
5. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010;55:773-99.
6. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19:1827-35.
7. Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77:897-903.
8. Novartis Clinical Trial Results Database. A 12-week, open label, multicentre, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer-HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis. Accessed 25 May 2012.
9. Chen JB, Chiang SS, Chen HC, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomised, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16:743-50.
10. Chen JB, Chiang SS, Chen HC, et al. SBR759 is more effective than sevelamer hydrochloride in sustaining serum phosphate reduction in hemodialysis. J Am Soc Nephrol. 2010;21:647A.
11. Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2008;12:55-61.
12. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770-9.
13. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34-8.
14. Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010;5(Suppl 1):S31-40.
15. Akiba T, Chen JB, Chen HC, et al. SBR759 is well-tolerated with good gastrointestinal tolerability profile compared to Sevelamer Hydrochloride. J Am Soc Nephrol. 2010;21:647A.
16. Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32:439-46.